Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prasugrel receives CHMP nod

This article was originally published in Scrip

Executive Summary

The EU's CHMPhas granted a positive opinion recommending approval of LillyandDaiichi Sankyo's novel antiplatelet therapy prasugrel (Efient, 5mg and 10mg film-coated tablets), giving a boost to the product which has twice seen delays in its US approval process. In Tokyo, shares in Daiichi Sankyo surged by nearly 6% on the news on December 19th, regaining some of the ground lost since September when the FDA failed to complete its review by the PDUFA user fee deadline.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts